| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Guest Access | Sign In via User Name/Password
|
|
|
|||||||
Guest Access | Sign In via User Name/Password |
|||||||||
1 From the Pulmonary Department, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
2 From the Department of Medicine, Pierre Bénite Hospital, Lyon, France
3 From the Pulmonary Department, Bretonneau Hospital, Tours, France
4 From the Bacteriology Laboratory, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
5 From the Abbott Laboratories, Rungis, France
Mycobacterium avium complex infections, common in patients with AIDS as either pulmonary or disseminated disease, are infrequent in patients without AIDS. Participants were 45 HIV-negative patients with lung disease and positive sputum cultures for M avium; 10 had documented immunocompromise, and 24 had preexisting lung disease. Clarithromycin dosage was 500 to 2,000 mg daily (mean±SD=1,633±432 mg). The drug was administered either alone (n=14) or in combination with rifampin (n=8), aminoglycoside (n=1), quinolone (n=10), clofazimine (n=18), isoniazid (n=5), ethambutol (n=9), pyrazinamide (n=1), or minocycline (n=6). At 3 months, 36 patients among 39 bacteriologically assessed had negative sputum cultures, 3 had positive culture, 3 were dead, and 3 discontinued treatment. At the end of treatment, 32 patients remained negative, 7 were positive. The success rate was 15 of 22 (64%) in patients previously treated with antimycobacterial drugs for M avium disease and 17 of 23 (74%) in new patients. Adverse effects included mild hearing loss (n=4), increase in liver enzyme levels (n=5), and gastrointestinal pain (n=10, two of whom had to stop treatment). Patients stopped treatment after 300±186 days due to side effects (3), death (4), or the patient's (5) or physician's decision (33). During the follow-up, one patient suffered a relapse with peripheral lymph nodes. A daily dose of 30 mg/kg of clarithromycin in the treatment of M avium infections appears to be effective and safe. Concomitant drug therapy should be assessed for its ability to prevent relapse.
Key Words: clarithromycin • lung infection • macrolides • mycobacterial infection • Mycobacterium avium complex
Submitted on December 30, 1994
Accepted on August 5, 1994
This article has been cited by other articles:
|
|
 |
|
  E. A. Waller, A. Roy, L. Brumble, A. Khoor, M. M. Johnson, and J. L. Garland The Expanding Spectrum of Mycobacterium avium Complex-Associated Pulmonary Disease. Chest, October 1, 2006; 130(4): 1234 - 1241. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. H. Ramadan and A. A. El Solh An Update on Otolaryngology in Critical Care Am. J. Respir. Crit. Care Med., June 15, 2004; 169(12): 1273 - 1277. [Full Text] [PDF]
|
|
|
|
|
|
S. K. Field and R. L. Cowie Treatment of Mycobacterium avium-intracellulare complex Lung Disease With a Macrolide, Ethambutol, and Clofazimine Chest, October 1, 2003; 124(4): 1482 - 1486. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 The Research Committee of the British Thoracic Soc Pulmonary disease caused by M. malmoense in HIV negative patients: 5-yr follow-up of patients receiving standardised treatment Eur. Respir. J., March 1, 2003; 21(3): 478 - 482. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Shiraishi, Y. Nakajima, K. Takasuna, T. Hanaoka, N. Katsuragi, and H. Konno Surgery for Mycobacterium avium complex lung disease in the clarithromycin era Eur. J. Cardiothorac. Surg., February 1, 2002; 21(2): 314 - 318. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Lang-Lazdunski, C. Offredo, F. Le Pimpec-Barthes, C. Danel, A. Dujon, and M. Riquet Pulmonary resection for Mycobacterium xenopi pulmonary infection Ann. Thorac. Surg., December 1, 2001; 72(6): 1877 - 1882. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-i. Ashitani, H. Mukae, T. Hiratsuka, M. Nakazato, K. Kumamoto, and S. Matsukura Plasma and BAL Fluid Concentrations of Antimicrobial Peptides in Patients With Mycobacterium avium- intracellulare Infection Chest, April 1, 2001; 119(4): 1131 - 1137. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Research Committee of the British Thoracic Society First randomised trial of treatments for pulmonary disease caused by M avium intracellulare, M malmoense, and M xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol Thorax, March 1, 2001; 56(3): 167 - 172. [Abstract] [Full Text]
|
|
|
|
|
|
E. TANAKA, T. KIMOTO, K. TSUYUGUCHI, I. WATANABE, H. MATSUMOTO, A. NIIMI, K. SUZUKI, T. MURAYAMA, R. AMITANI, and F. KUZE Effect of Clarithromycin Regimen for Mycobacterium avium Complex Pulmonary Disease Am. J. Respir. Crit. Care Med., September 1, 1999; 160(3): 866 - 872. [Abstract] [Full Text]
|
|
|
|
|
|
Diagnosis and Treatment of Disease Caused by Nontuberculous Mycobacteria Am. J. Respir. Crit. Care Med., July 1, 1997; 156(2): 1 - 25. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
